Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, 2-Part, Crossover Trial to Evaluate the Effect of Carbetocin on the QT/QTc Interval in Healthy Subjects

NCT05924321 is registered in ClinicalTrials.gov with Ferring Pharmaceuticals as lead sponsor.

NCT NCT05924321
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05924321 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, 2-Part, Crossover Trial to Evaluate the Effect of Carbetocin on the QT/QTc Interval in Healthy Subjects
Lead sponsor
Ferring Pharmaceuticals
Phase
Phase 1
Overall status
Completed
Start date
May 25, 2023
Completion date
September 21, 2023
Enrollment
40 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

postpartum hemorrhage